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The calcium/calmodulin-gated KCa3.1 channel regulates normal and
abnormal mitogenesis by controlling K+-efflux, cell volume, and membrane
hyperpolarization-driven calcium-entry. Recent studies suggest modulation of KCa3.1
by omega-3 fatty acids as negative modulators and impaired KCa3.1 functions in the
inherited lysosomal storage disorder (LSD), Fabry disease (FD). In the first part of present
study, we characterize KCa3.1 in murine and human fibroblasts and test the impact of
omega-3 fatty acids on fibroblast proliferation. In the second, we study whether KCa3.1 is
altered in the LSDs, FD, and Niemann-Pick disease type C (NPC). Our patch-clamp and
mRNA-expression studies on murine and human fibroblasts show functional expression
of KCa3.1. KCa currents display the typical pharmacological fingerprint of KCa3.1:
Ca2+-activation, potentiation by the positive-gating modulators, SKA-31 and SKA-121,
and inhibition by TRAM-34, Senicapoc (ICA-17043), and the negative-gating modulator,
13b. Considering modulation by omega-3 fatty acids we found that α-linolenic acid (α-LA)
and docosahexanenoic acid (DHA) inhibit KCa3.1 currents and strongly reduce fibroblast
growth. The α-LA-rich linseed oil and γ-LA-rich borage oil at 0.5% produce channel
inhibition while α-LA/γ-LA-low oils has no anti-proliferative effect. Concerning KCa3.1 in
LSD, mRNA expression studies, and patch-clamp on primary fibroblasts from FD and
NPC patients reveal lower KCa3.1-gene expression and membrane expression than
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in control fibroblasts. In conclusion, the omega-3 fatty acid, α-LA, and α-LA/γ-LA-rich
plant oils, inhibit fibroblast KCa3.1 channels andmitogenesis. Reduced fibroblast KCa3.1
functions are a feature and possible biomarker of cell dysfunction in FD and NPC and
supports the concept that biased lipid metabolism is capable of negatively modulating
KCa3.1 expression.
Keywords: KCa3.1/SK4 channel, linolenic acids, fabry disease, fibroblasts, ion channel pharmacology
INTRODUCTION
The intermediate-conductance calcium/calmodulin-gated
potassium channel KCa3.1 (encoded by the KCNN4 gene)
is expressed in a variety of tissues such red and white blood
cell lineage, epithelia, and endothelia (Wei et al., 2005).
Notably, induction of KCa3.1 is suspected to drive abnormal
cell proliferation, inflammation, and pathological organ
remodeling (fibrosis) in heart, kidneys, lungs, some cancers, and
atherosclerosis and neo-angiogenesis (for review see: Roach et al.,
2013; Feske et al., 2015; Huang et al., 2015; Köhler et al., 2016).
Accordingly, pharmacological modulation of the channel is
considered a way to treat disease in humans. Hence, several small
molecule blockers and positive and negative-gating modulators
are available and Icagen compound, Senicapoc, was found
clinically safe (for recent review see: Christophersen and Wulff,
2015). Also the endogenous omega-6 fatty, arachidonic acid (AA)
and AA-metabolites such as some 11,12 epoxyeicosatrienoic
acid and 20-hydroxyeicosatetraenoic acid (20-HETE), have
been found to inhibit cloned human KCa3.1 that required
mechanistically the inner pore lining amino acid residues, T250
and V275 as putative interaction sites (Hamilton et al., 2003;
Kacik et al., 2014). However, the cell biological meaning of this
modulation of KCa3.1 by omega-3/6 fatty acid is unclear.
Interestingly, KCa3.1-functions have been suggested to be
compromised in Fabry disease (FD; Choi et al., 2014, 2015;
Choi and Park, 2016), a X-linked lysosomal storage disorder
(LSD), in which defective lysosomal targeting of mutated α-
galactosidase A encoded by the GLA gene causes globotriaosyl-
ceramide (Gb3) accumulation. Mechanistically, Gb3 has been
suggested to downregulate KCa3.1-expression, fibroblast growth,
differentiation into myofibroblasts, and collagen expression.
These impairments could be reversed by channel activation (Choi
et al., 2015).
In keeping with these previous findings, we characterized in
the first part of this study KCa3.1 functions in a murine fibroblast
cell line and human dermal fibroblasts and tested inhibitory
actions of α-linolenic acid (α-LA) and docosahexaenoic acid
(DHA) on channel functions and fibroblast mitogenesis.
In the second part, we tested whether disease-related
impairments of fibroblast KCa3.1 are features of the two LSDs,
FD and Niemann-Pick disease type C (NPC).
In this study, we found that murine and human dermal
fibroblasts express amounts of functional KCa3.1 channels. We
show strong sensitivity of fibroblast mitogenesis to α-LA and
DHA.
KCa3.1 gene expression and KCa3.1 currents were reduced in
two different LSDs.
METHODS
Cells and Patients
Fibroblast Cultures
Murine 3T3-L1 fibroblasts were cultured in DMEM
supplemented with 10% FCS (Biochrom KG, Berlin, Germany).
Primary human dermal fibroblast cultures were made from
punch biopsies from FD and NPC patients as well as from a
healthy donor (according to the guidelines of the local Ethics
Committee, permit no. PI16/0227). Fibroblasts from patients’
skin biopsies were cultured in DMEM supplemented with 10%
FCS (Biochrom KG, Berlin, Germany) and cells were used at
passages 1–4. For patch-clamp experiments, cells were seeded on
coverslips and used within 24 h.
This study was carried out in accordance with the
recommendations of the local Ethics Committee (CEICA)
with written informed consent from all subjects. All subjects gave
written informed consent in accordance with the Declaration
of Helsinki. The protocol was approved by the local Ethics
Committee (CEICA).
Patients
The FD patients included in this study displayed the classic
FD phenotypes: A 32-years old male (p.Y216fs∗15 hemizygous)
showed acroparesthesias, hypohidrosis, and mild proteinuria
and renal glycolipid deposits and frequent gastrointestinal
disturbances. The 56-years old female (p.G183V heterozygous)
showed despite her heterozygous genotype clear and typical
clinical symptoms like acroparesthesias, hypohidrosis, mild
proteinuria, and renal glycolipid deposits, cardiac arrhythmias,
and frequent gastrointestinal disturbances. An atypical 50-
years old female FD patient harbored a complex intronic
haplotype (CIH) (c.-10C > T, c.369 + 990C > A, c.370-81_370-
77delCAGCC, c.640-16A > G, c.1000-22C > T, heterozygous)
(Gervas-Arruga et al., 2015) and showed ischemic coronary
artery disease with repetitive balloon catheter inventions, stent
implantations, and valve insufficiency. A 41-years old male FD
patient with a complex intronic haplotype (CIH) (c.-10C > T,
c.369 + 990C > A, c.370-81_370-77delCAGCC, c.640-16A >
G, c.1000-22C > T, hemizygous; Gervas-Arruga et al., 2015)
who had a different phenotype with mild renal deposits in
podocytes and normal glomerular function, but showed severe
acroparesthesias and two transitory episodes of ischemic stroke.
The Fabry patients started enzymatic replacement therapy
in 2011 with agalsidase alfa weekly and are clinically stable at
present.
The 31-years old male NPC patient (NPC1 p.Q775P
heterozygous) did not show neurological manifestation yet.
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The patient developed severe spleen enlargement with extreme
invasion of foam cells and was splenectomized.
Patch-Clamp Electrophysiology
In brief, Ca2+-activated K+ currents were measured in the
whole-cell configuration using an EPC10-USB amplifier (HEKA,
Electronics, Lambrecht-Pfalz, Germany) and a K pipette solution
(intracellular) containing 1 µM Ca2+ free (in mM): 140 KCl, 1
MgCl2, 2 EGTA, 1.71 CaCl2 (1 µM [Ca2+]free), and 5 HEPES
(adjusted to pH 7.2 with KOH). The bath solution contained (in
mM): 140 NaCl, 5 KCl, 1 MgSO4, 1 CaCl2, 10 glucose, and 10
HEPES (adjusted to pH 7.4 with NaOH). For maximal KCa3.1-
activation we applied SKA-31 or SKA-121 at a concentration
of 1 µM that is ∼10-times the concentration for half-maximal
activation.
For data acquisition and analysis we used the patch-master
program (HEKA). Ohmic leak currents of up to 1 nS were
subtracted where appropriate. We quantified outward currents
at a 0 mV holding potential (to avoid contamination with non-
selective cation currents and chloride currents). Capacitance
values (a measure of cell surface and thus cell size) were
significantly higher in fibroblasts from female and male FD
GLA Intronic hemizygous than in Ctrl (Ctrl, 38 ± 5 pF; ♀ FD
GLA Intronic heterozygous, 80 ± 12 pF (P < 0.05 vs. Ctrl,
Student’s T-Tests); ♂ FD GLA Intronic hemizygous, 107 ± 10
pF (P < 0.05 vs. Ctrl, Student’s T-Tests); ♀ FD GLA p.G183V
heterozygous, 24 ± 5 pF; ♂ FD GLA p.Y216fs∗15 hemizygous,
50 ± 8 pF, n = 6; ♂ NPC1 p.Q775P heterozygous, 34 ± 6 pF,
n= 5).
Gene Expression Studies
RNA Isolation and Reverse Transcription
Total RNA was isolated with TriReagent (Sigma, Saint Louis,
Missouri, USA) following manufacturer’s protocol, and further
purified using RNA Clean-up and Concentration-Micro-
Elute kit (Norgen Biotek, Thorold, Canada). Genomic DNA
digested using the Ambion DNA-free kit (Invitrogen, Carlsbad,
California, USA). Quantity and purity of extracted RNA
were determined by spectrophotometry (NanoDrop 1000,
Thermofisher, Waltham, MA) and stored at −80◦C for later use.
Integrity of RNA samples and successful digestion of genomic
DNA were ensured by gel electrophoresis. Reverse transcription
was performed with 600 ng of total RNA by using the SuperScript
III reverse transcriptase (Invitrogen, Carlsbad, California,
USA) and random hexamers following the manufacturer’s
protocol.
Quantitative RT-PCR
cDNA obtained from 20 ng of total RNA was amplified in
triplicates using the SYBR Select Master Mix and a StepOnePlus
Real-Time PCR system (Applied Biosystems, Foster City,
California, USA) using the following cycle protocol: 95◦C, 15 s
and 60◦C, 60 s repeated for 40 cycles. As final step, a melting
curve analysis was carried out to verify correct amplification. The
following primers were used: KCa3.1-F: 5′-CATCACATTCCT
GACCATCG-3′; KCa3.1-R: 5′-ACGTGCTTCTCTGCCTTGTT-
3′, GAPDH-F: 5′-GGGATCAATGACCCCTTCAT-3′; GAPDH-
R: 5′-GCCATGGAATTTGCCAT-3.
Data were analyzed with LinRegPCR software (Ruijter et al.,
2009) and gene expression levels relative to GAPDH expression
as reference gene and normalized to control were calculated using
the formula:
% of Control =
Efficiency(KCa3.1)Cq(Control)−Cq(Sample)
Efficiency(GAPDH)Cq(Control)−Cq(Sample)
Proliferation Assay
Measurements of cell proliferation were done using the vital
colorimetric Janus-Green assay, with some modifications as
described previously in more detail (Olivan-Viguera et al.,
2013). In brief, 3T3-L1 fibroblasts were seeded at the same
density (80,000 cells/well) in 12-well-plates (flat bottom, Costar,
Corning Inc. NY, USA) and cultured in DMEM medium
supplemented with L-glutamine, with 10% fetal bovine serum
and 1% penicillin/streptomycin, in the presence of DHA (10
µM), α-LA (10–500µM), borage oil, argan oil, onagra oil, linseed
oil (0.5%), or vehicle (DMSO 0.1% for DHA or DMSO 0.5%
for α-LA, borage oil, argan oil, onagra oil, and linseed oil).
Final DMSO concentrations were the same for each compound
and its control. At days 0, 1, 2, 3, and 4 (confluence) cells
were fixed with formalin (10% in deionized water). Thereafter,
cells were stained for 10 min with 0.3% Janus Green B dye
(Sigma-Aldrich) at room temperature at constant stirring. Cells
were then de-stained with water and dye was eluted with 0.5
M HCl at room temperature at constant stirring for 15 min.
Absorbance values at 595 nmwere determined using amicroplate
reader (Sinergy HT, Biotek, USA). Each compound was tested
in three independent experiments. In other experiments, high
power field images of human fibroblast cultures were taken
at day 0 and 4 and the increase of area occupancy was
determined by using the Image J software. We did not find
gross differences between controls (increase in area occupancy:
58%) and FD patients (male GLA p.Y216fs∗15 hemi, 57%; female
GLA p.G183V heterozygous, 86%) and the male NPC1 p.Q775P
heterozygous, 93%).
Compounds
α-LA and docosahexaenoic acid (DHA) were purchased
from Sigma-Aldrich (Deisenhofen, Germany) and were pre-
diluted in DMSO giving a concentration of 1–500 µM (final
concentration of DMSO 0.1–0.5%). TRAM-34, Senicapoc,
SKA-31, and SKA-121 were a kind gift from Prof. Heike Wulff,
Pharmacology at University of California, Davis. 13b ([3,5-
bis[(3-fluoro-4-hydroxy-benzoyl)-oxymethyl]phenyl]methyl
3-fluoro-4-hydroxy-benzoate) was a kind from Prof. Robert
Kiss, Laboratoire de Toxicologie, Institut de Pharmacie, ULB,
Belgium. All other drugs were purchased from Sigma-Aldrich
(Deisenhofen, Germany). Pure plant oils were purchased
from a local herbalist’s shop and pre-diluted in DMSO (final
concentration of both, 0.5%).
Frontiers in Physiology | www.frontiersin.org 3 January 2017 | Volume 8 | Article 39
Oliván-Viguera et al. Regulation of KCa3.1 by α-LA and in LSDs
RESULTS
Characterization of KCa3.1 in Murine
3T3-L1-Fibroblasts and Impact of the
Omega-3 Fatty Acids, α-LA and DHA, on
3T3-L1 Mitogenesis in vitro
In murine 3T3-L1 fibroblasts, KCa3.1 currents developed after
breaking into the whole-cell mode and concomitant infusion of
Ca2+ via the patch-pipette. KCa3.1 currents displayed voltage-
independence (for traces see Figure 1A, left panel; for additional
details see Oliván-Viguera et al., 2015b). Pre-activation of the
KCa3.1 currents and concomitant K+-eﬄux was accompanied
by a shift of the reversal potential (Erev) from basal (Erev, ≈ −25
± 7 mV, immediately measured after breaking into the whole-cell
mode) to a more negative Erev of≈−55± 9mV.
The positive-gating modulators of KCa3.1, SKA-31 (1 µM,
Sankaranarayanan et al., 2009) strongly potentiated the calcium-
pre-activated currents by 19-fold and further shifted the Erev
to ≈ −76 ± 3 mV (for trace see Figure 1A, right panel, and
summary data in Figure 1B, left panel). The classical KCa3.1
blocker, TRAM-34 (Wulff et al., 2000), virtually abolished the
complete potentiated KCa3.1 currents (Figure 1B, right panel).
Regarding omega-3 fatty acids, α-LA and DHA, both at 10
µM, also abolished the complete SKA-31-potentiated KCa3.1
current and shifted Erev back to more positive values, Erev ≈−11
± 4 mV (for trace see Figure 1A and summary data Figure 1B,
right panel).
QRT-PCR amplified mRNA-KCa3.1 in murine 3T3-L1
fibroblasts and expression levels were 0.02% of the reference gene,
GAPDH, thus demonstrating intact gene expression of KCa3.1 in
these cells.
Concerning the impact of α-LA on fibroblast proliferation,
our Janus Green B colorimetric assay of cell proliferation revealed
that α-LA concentration-dependently inhibited cell growth, with
half-maximal inhibition at ≈100 µM (Figures 2A,C). However,
concentrations ≥250 µM appeared to be cytotoxic in this assay.
We also observed inhibition of cell growth when using DHA
(Figures 2B,C), although DHA was seemingly more potent, with
half-maximal inhibition at≈10 µM.
Considering the reported beneficial effects of dietary
supplementation of α-LA and α-LA-rich plant oils on
autoimmune diseases and chronic inflammation such as
multiple sclerosis, rheumatoid arthritis, psoriasis, chronic
inflammatory bowel disease, or atopic dermatitis (Macfarlane
et al., 2011; Wergeland et al., 2012; Yates et al., 2014) we were
curious to learn whether α-LA-rich plant oils were also capable
of inhibiting KCa3.1. The α-LA-rich linseed oil (from Linum
usitatissimum and γ-LA-rich borage seed oil [Borago officinalis
(Tso et al., 2012) produced significant channel inhibition at 1%
while argan oil (from kernels of the argan tree (Argania spinosa
L. (Charrouf and Guillaume, 2008) and onagra oil (from evening
primrose seeds, Oenothera biennis L. (Fan and Chapkin, 1998)]
with low levels of α-LA (<1%) and γ-LA (<10%), respectively,
did not produce significant channel inhibition (Figure 3A).
FIGURE 1 | Inhibition of KCa3.1 in murine 3T3-L1 fibroblasts by DHA and α-LA: (A) on left: Exemplary whole-cell current recordings of basal currents (after
breaking into the whole-cell mode) and of pre-activated KCa3.1-currents by calcium. On right: SKA-31-potentiation of KCa3.1 currents (pre-activated by calcium) and
inhibition of the complete potentiated current by DHA. (B) Summary data showing potentiation of calcium-pre-activated KCa3.1 currents by SKA-31 and inhibition of
the complete SKA-31-potentiated KCa3.1 currents by DHA and α-LA. Data are means ± SEM. *P < 0.05, Student’s T-test.
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FIGURE 2 | Inhibition of 3T3-L1 fibroblast mitogenesis by α-LA and DHA: (A) Concentration-dependent inhibition of cell proliferation by α-LA. (B) Inhibition of
proliferation by DHA. Data are means ± SEM. *P < 0.05, Student’s T-tests. (C) High power field images of 3T3-L1 fibroblasts after 4 days of culture in the presence of
DMSO (vehicle, 0.5%), DHA 10 µM and α-LA 100 µM.
Concerning 3T3-L1 fibroblast proliferation, linseed oil and
borage oil produced significant inhibition of mitogenesis
(Figures 3B,C) while onagra oil showed no significant effect
on proliferation. Argan oil was found to be cytotoxic as cell
numbers instantaneously decreased after application to cells
(Figures 3B,C).
Characterization of KCa3.1 in Cultured
Human Dermal Fibroblasts and
Comparisons of Fibroblast KCa3.1
Functions in FD and NPC Patients
While KCa3.1 in murine fibroblast lines is well-characterized
(Olivan-Viguera et al., 2013), information on KCa3.1 function
and membrane expression in human dermal fibroblasts is scarce
if compared to KCa3.1 in human fibroblasts in other tissues
(Roach et al., 2014, 2015; Friebel et al., 2015). Moreover, altered
KCa3.1 functions have been described in murine models of FD
and FD patients (Choi et al., 2014, 2015; Choi and Park, 2016),
suggesting a detrimental impact of lysosomal lipid accumulation
on KCa3.1 protein expression or function.
Here, our mRNA-expression studies revealed substantial
lower mRNA-KCa3.1 amounts in cell extracts from the male
hemizygous FD-p.Y216fs∗15 patient (Figure 4), the male NPC
patient, but not from the female heterozygous FD-p.G183V
patient.
Our patch-clamp studies detected KCa3.1 currents in human
control fibroblasts with the same biophysical and pharmacology
profile as in 3T3-L1 fibroblasts and of cloned human KCa3.1, i.e.,
calcium-activation, potentiation by SKA-31 (29-fold) or by SKA-
121(13-fold), a related, more selective KCa3.1 activator (Coleman
et al., 2014; for traces and summary data see Figure 5A).
This potentiated current was virtually abolished by TRAM-34,
Senicapoc, the negative-gating modulator, 13b (Olivan-Viguera
et al., 2013), and α-LA (Figure 5A, right panel).
The comparison of SKA-potentiated and maximal KCa3.1-
currents densities in the LSD patients revealed a clear
trend toward lower functional KCa3.1 expression in the two
hemizygous male FD patients and the male NPC patient but
not in heterozygous female FD patients (Figure 5B): Mean
KCa3.1 current densities were reduced to 5 and 20% of control
in the two male FD, to 48 and 72% of control in the two
female heterozygous FD patients, and to 13% in the male NPC
patient.
Together, our data suggests that KCa3.1-gene expression and
membrane expression of the channel are impaired in fibroblasts
of hemizygous male FD patients and in the male NPC patients,
while KCa3.1-functions in fibroblasts from heterozygous female
FD patients are largely conserved.
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FIGURE 3 | Inhibition of KCa3.1 currents and 3T3-L1 fibroblast proliferation by plant oils. (A) Summary data showing the efficacy of different plant oils to
inhibit KCa3.1 currents. A, argan oil; B, borage oil; O, onagra oil; L, linseed oil. α-LA at 10 µM served as positive control. The concentration of the oils was 0.5%. (B)
Efficacy of plant oils to inhibit cell proliferation. Note that argan oil produced a decrease in cell number after 24 and 48 h, which was indicative of high cytotoxicity in
this assay. Data are means ± SEM. *P < 0.05, Student’s T-test. (C) High power field images of 3T3-L1 fibroblasts after 4 days of culture in the presence of DMSO
(vehicle), linseed oil, borage oil, onagra oil, and argan oil (0.5%).
DISCUSSION
KCa3.1 channel functions have been linked to abnormal cell
proliferation, pathological tissue remodeling and fibrosis of
a variety of organs, chronic inflammation, and autoimmune
diseases (Wulff and Zhorov, 2008; Roach et al., 2013; Wulff
and Köhler, 2013; Feske et al., 2015; Huang et al., 2015; Köhler
et al., 2016). Accordingly, pharmacological inhibition of KCa3.1
has been suggested to be a treatment strategy for such disease
states. In the present study we investigated: (1) the modulation of
fibroblast KCa3.1 channels and fibroblast proliferation by omega-
3 fatty acids, α-LA and DHA, as well as α-LA/γ-LA-rich and -low
plant oils. (2) KCa3.1 functions in FD and NPC fibroblasts.
Here, we demonstrated KCa3.1 functions with the typical
pharmacological fingerprint in murine 3T3-L1 fibroblasts and
primary human dermal fibroblasts and showed inhibition of the
channel by α-LA and DHA as well as potent anti-proliferative
effects of these omega-3 fatty acids in vitro. Moreover, we
demonstrated inhibition of KCa3.1 functions by α-LA- and γ-
LA-rich plant oils and strong inhibition of 3T3-L1 fibroblast
by linseed oil and borage oil, suggesting them as non-synthetic
channel inhibitors with potential utilities for alleviating diseases
states characterized by excessive cell proliferation, fibrosis, and
chronic inflammation.
Impaired KCa3.1 functions have also been suggested to be
a result of lipid overload in FD (Choi et al., 2014). Here, we
demonstrated conserved but significantly reduced functional
KCa3.1 channel membrane expression and mRNA expression in
classical and atypical male FD patients and aNPC patient, KCa3.1
functions, suggesting impaired expression of KCa3.1 as potential
biomarker of these LSDs.
Lipid regulation of K channels is a rather new field in ion
channel research. So far, activation as well as inhibition of K
channels has been described: Omega-6 and -3 fatty acids have
been reported to activate KCa1.1 channels (a.k.a. BKCa encoded
by the KCNMA1 and KCNMB1-3 genes; Kirber et al., 1992; Wei
et al., 2005; Moreno et al., 2012). Likewise, the K2P channels,
TWIK-2/2, TREK1/2, and TRAAK, were activated by omega-
3/6 acids (Maingret et al., 1999; Wei et al., 2005; Nielsen et al.,
2013). Regarding the KCa2/3 gene family, cloned KCa3.1 was,
however, inhibited by omega-3/6 fatty acids (Hamilton et al.,
2003; Kacik et al., 2014) and this inhibition required the inner-
cavity lining amino acid residues T250 and V275 that are not
present in corresponding sites in the abovementionedK channels
families and in KCa2 channels. In the present study we provided
new evidence for KCa3.1-inhibition by α-LA and also showed
for the first time that also α-LA/γ-LA-containing plant oils (at
0.5%) were capable of efficiently inhibiting KCa3.1. However,
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FIGURE 4 | Comparison of KCa3.1 gene expression and KCa3.1
current densities in fibroblasts from FD and NPC patients. Results from
qRT-PCR showing gene expression of KCa3.1m in FD and NPC patients
relative to control (Ctrl). Data are means of triplicates ± SEM.
inhibitory activity clearly depended on high α-LA or γ-LA-
content (>30%) since oils with low α-LA/γ-LA content failed
to produce significant inhibition, which could be explained by
the high contents of saturated or mono-saturated fatty acids that
were not active on KCa3.1 but competed with α-LA as suggested
previously for P450-derived metabolites of arachidonic acid such
as 5,6-EET, 8,9-EET, 5,6-DiHETE, and saturated arachidic acid
(Kacik et al., 2014).
The possible consequences of KCa3.1-inhibtion by α-LA for
fibroblast proliferation were not established. Here, our study
extended the current knowledge by showing that the α-LA- and
γ-LA-rich plant oils, linseed oil and borage oil, respectively,
exerted strong anti-proliferative activity. The γ-LA-low onagra
oil was inefficient, a finding that further fostered the notion that
for efficient targeting KCa3.1 and inhibition of cell proliferation
a high-α-LA-/γ-LA was needed. Concerning argan oil, we cannot
judge on possible anti-proliferative actions because the oil was
found to be cytotoxic at the concentration used here.
Concerning the magnitude of inhibition of fibroblast
proliferation the effect of α-LA and α-LA-rich oils were similar
to reported effects of a synthetic negative-gating modulator of
KCa3.1 and a classical pore blocker (Olivan-Viguera et al., 2013;
Roach et al., 2015). However, here we do not wish to exclude
other mechanisms by which α-LA and α-LA-/γ-LA-rich oils
reduce fibroblast proliferation.
Dietary supplementation with α-LA and α-LA-containing
oils has been suggested since long to have therapeutic utilities
in several autoimmune diseases of skin and bowel, multiple
sclerosis, and rheumatoid arthritis (for review see: Macfarlane
et al., 2011; Wergeland et al., 2012). Some of these effects have
been proposed to rely on interference with e.g., pro-inflammatory
prostaglandin production/metabolism (for review see Yates et al.,
2014).
Here, we suggest that inhibition of KCa3.1 could be an
additional mechanism of action. KCa3.1 inhibitors have been
shown to suppress pro-inflammatory cytokine production in
immune cells and to reduce pathological organ remodeling and
fibrosis in experimental models. Therefore, from the perspective
of phytopharmacology, our data fostered the view that inhibition
of KCa3.1 in psoriatic lesions of skin or the chronically inflamed
bowel by topically or systemically applied α-LA/γ-LA-rich
plant oils and/or dietary supplementation with α-LA/γ-LA-rich
plant oils or by synthetic blockers (Wulff and Köhler, 2013;
Christophersen and Wulff, 2015) could be an alternative and
economic treatment for patients with mild forms of disease or an
adjuvant treatment in more severely affected patients receiving
immune suppressive therapy.
It should also be considered that the plant oils used in this
study are of complex composition and the nature of the active
compounds is still unclear. So, we do not wish to exclude
that other compounds than α-LA caused some of the anti-
proliferative effects on 3T3 fibroblasts. Yet, it was striking that the
anti-proliferative effects correlated with the quantity of α-LA or
γ-LA suggesting that α-LA/γ-LA played a major role here. In this
regard, it is worth speculating that the cytotoxic effects caused by
argan oil likewise rely on so far undefined compounds in this oil.
Dysfunction of lysosomal lipid metabolism/transport has
recently been shown to impair KCa3.1-functions and mRNA-
expression and reducedmembrane surface expression by lowered
phosphatidylinositol 3-phosphate as reason for these alterations
(Choi et al., 2015; Choi and Park, 2016). In the present study,
we provided additional evidence for such defective KCa3.1-
regulation in FD fibroblasts and also in NPC fibroblasts from a
male patient, which seemed predominantly to rely on impaired
de novo-KCa3.1 gene expression, thus similar to that was found
in earlier studies (Choi et al., 2015; Choi and Park, 2016). To
the contrast, membrane expression—albeit at lower density—
and activation was still intact in most cells, suggesting no
major disturbances in membrane trafficking or function in the
fibroblasts from FD patients investigated in our study.
Interestingly, the alterations were exclusively present in
dermal fibroblasts of male FD patients with a classical missense
mutation of this X-linked disease and an atypical complex
intronic haplotype that have been reported to produce FD
pathologies. In contrast, heterozygous female carriers with
classical and atypical mutations, who may or may not develop
clinically relevant symptoms depending on whether they have the
mutated allele or the healthy allele as active copy, showed largely
conserved functions of the channel in their dermal fibroblasts.
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FIGURE 5 | Pharmacological characteristics of KCa3.1 in human fibroblasts. (A) On left: Exemplary traces showing the SKA-31 (1 µM)-potentiated fibroblast
KCa3.1 current and inhibition of the complete SKA-31-potentiated KCa3.1-current by 13b (1 µM). In middle: Potentiation of K currents (background K currents or
calcium-pre-activated by calcium) by SKA-31 (n = 4) and SKA-121 (n = 5). On right: Inhibition of the SKA-potentiated current by TRAM-34 (n = 4), Senicapoc (n = 2),
13b (n = 10), and α-LA (n = 2). (B) Mean SKA-potentiated KCa3.1-current densities in Ctrl, FD, and NPC patients. Percentage of cells displaying functional KCa3.1:
Ctrl, 4 out of 4 cells (100%); ♀ FD GLA Intronic heterozygous, 13 out of 20 (65%); ♂ FD GLA Intronic hemizygous 1 out of 15 (7%); ♀ FD GLA p.G183V heterozygous,
5 out of 6 (83%); ♂ FD GLA p.Y216fs*15 hemizygous, 4 out of 6 (67%); ♂ NPC1 p.Q775P heterozygous, 3 out of 5 (60%). Data in bar chart are means ± SEM, *P <
0.05, Student’s T-test.
Together, this suggested that low KCa3.1-mRNA expression in
skin fibroblasts could be at least an additional biomarker of
FD-disease or disease activity in male FD patients and in NPC
patients.
Interestingly, in another study on KCa3.1 functions in
type-1 and -3 Gaucher patients we found a defect in
the physiologically occurring up-regulation of KCa3.1 during
monocyte-to-macrophage differentiation (Oliván-Viguera et al.,
2015a), further suggesting that KCa3.1 dysregulation is perhaps
a more general feature of LSDs and cellular pathophysiology.
But again, the pathophysiological mechanism and significance
remain unclear.
At this point, we would like to remind the reader that KCa3.1
functions in disease states have been so far related to pro-
proliferative and -inflammatory processes and pathological organ
remodeling such as kidney and lung fibrosis (Wulff and Zhorov,
2008; Roach et al., 2013; Wulff and Köhler, 2013; Feske et al.,
2015; Huang et al., 2015; Köhler et al., 2016). Accordingly,
pharmacological inhibition of KCa3.1 has been proposed as
pharmacological strategy to treat chronic inflammation and
organ fibrosis. So, whether or not KCa3.1—albeit reduced—is
drug target in FD and associated pathologies such progressive
heart and kidney disease, aneurism, and angiokeratoma cannot
be decided at present. Still, there is the possibility that inhibition
of KCa3.1 by small molecules or α-LA-/γ-LA-rich oils as
dietary supplement may delay disease progression in LSD
patients who develop organ pathologies characterized by chronic
inflammation and fibrosis.
There are some limitations concerning our patient study: First,
the number of patients studied here was relatively small, which is
a general limitation when studying these rare LSD with complex
and varying clinical pathology. However, the observed differences
in KCa3.1-expression and functions were still considerable (ca.
75% reduction) between controls and male FD patients. Here
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additional, mRNA expression analysis in a larger number and
other cohorts of patients will be needed to further establish
KCa3.1 as biomarker of FD and/or other LSD. Whether these
alterations were unique for FD disease remains unclear since a
male NPC patient showed similarly reduced KCa3.1 functions.
Secondly, in the present study we did not intent to reveal the
pathomechanism linking defects in lipid metabolism and lipid
overload to reduced KCa3.1 membrane functions, although lipid
overload affecting de novo-gene expression is likely to be a major
reason here.
In conclusion, the present study showed inhibition of
KCa3.1 functions and fibroblast mitogenesis by the α-LA-/γ-
LA-rich plant oils, in vitro. This suggests the utility of both
as dietary supplement or topical ointments to target these
pro-inflammatory and pro-mitogenic channels in cutaneous,
neuronal or intestinal autoimmune disease.
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